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Uremic hyperleptinemia: Adaptive or maladaptive?
Interest in the regulation of body weight and pathophys-
iology of obesity has been rekindled by the cloning of the
obese (OB or LEP) gene and identification of its protein
product leptin (Greek leptos, thin) [1]. The LEP gene is
expressed exclusively in fat cells, which remain the only
known source of the hormone leptin. Administration of
recombinant leptin elicits impressive biological effects in
mice. These include inhibition of food intake, stimulation
of energy expenditure, reversal of obesity, amelioration of
insulin resistance, and acceleration of sexual maturation.
Human fat cells synthesize and secrete leptin into the
circulation, and emerging data indicate that leptin is a
regulated hormone that may be involved in as yet unchar-
acterized aspects of human metabolism. Physiological fac-
tors associated with increased leptin secretion in humans
include female gender, weight gain, puberty, and overfeed-
ing; those associated with hypoleptinemia include fasting,
strenuous exercise, menopause, and senescence. The hor-
monal and metabolic factors that regulate leptin are incom-
pletely understood: Plasma leptin levels increase by ;40%
following prolonged insulin infusion [2], and by ;100%
within 48 hours of oral dexamethasone treatment [3].
Soon after leptin became measurable in humans, it was
discovered that many patients with end-stage renal disease
(ESRD) were hyperleptinemic, compared with healthy
control subjects [4, 5]. Possible mechanisms for hyperlep-
tinemia in ESRD patients include impaired clearance [5]
and/or increased synthesis. Using arteriovenous differ-
ences, net renal extraction has been estimated at ;12% of
circulating leptin in persons with normal kidneys, and ;0%
in patients with renal failure [5]. Nonetheless, 25% of
ESRD patients [especially those with a body mass index
(BMI) less than 24 kg/m2] maintain normal plasma leptin
levels [6]. It is unclear how leptin is eliminated in these
patients, but the ubiquity of leptin receptors suggests that
receptor-mediated disposal could occur in nonrenal tissues.
Thus, impaired renal elimination accounts for some but not
all of the elevation in plasma leptin that is observed in
ESRD; increased leptin synthesis (probably stimulated by
certain hormones that accumulate in renal failure) is a
possibility that awaits exploration. The relatively greater
magnitude of hyperleptinemia that has been reported in
patients treated by continuous ambulatory peritoneal dial-
ysis (CAPD) [6] suggests that peritoneal dialysis may be
less efficient in clearing leptin, or associated with a greater
stimulation of leptin synthesis, than is hemodialysis.
The pathophysiologic significance of circulating leptin
levels in ESRD patients is unclear. Conceivably, chronic
elevation of serum leptin could affect metabolic processes,
including appetite and nutritional status, if leptin receptors
are not down-regulated. In this issue of Kidney Interna-
tional, Dr. Fouque and colleagues determined the acute
effects of s.c. administration of recombinant human insulin-
like growth factor-I (IGF-I) with or without recombinant
human growth hormone (GH) on serum immunoreactive
leptin concentration in 8 lean patients with ESRD main-
tained on chronic hemodialysis [7]. During IGF-I treat-
ment, significant decreases were observed in serum insulin
and leptin (but surprisingly not GH) concentrations. Com-
bined treatment with IGF-I and GH increased serum
concentrations of insulin, GH, and leptin fivefold, sixfold,
and twofold, respectively. These results, if confirmed in a
larger study, would add appreciably to our understanding
of hormonal regulation of human leptin, albeit, among
renal-impaired persons. Regression analyses showed a re-
lationship between serum leptin and insulin (but not GH or
IGF-I) concentrations, which led the authors to suggest a
central role for insulin in explaining their main findings [7].
However, direct effects of IGF-I or GH on adipocyte leptin
synthesis have not been excluded, since leptin mRNA levels
were not reported.
The mean serum leptin concentration of the 8 ESRD
patients studied by Fouque et al [7] was similar to that of
healthy controls, most probably because of the small sam-
ple size and low BMI of these patients. However, the
overall mean serum leptin in the authors’ ESRD popula-
tion was much higher than that of healthy subjects [7],
consistent with numerous other reports [4–6]. The signifi-
cance of uremic hyperleptinemia is unknown. The relation-
ship between serum leptin and nutritional status in patients
with ESRD has not been tested directly in longitudinal
studies, but cross-sectional reports have showed no associ-
ation with recent weight change, serum albumin, or protein
catabolic rate [4, 6]. Obviously, further studies are needed
to delineate the pathophysiologic significance and wider
ramifications of circulating leptin levels in renal failure,
especially in light of the high mortality associated with
ESRD [8]. If future studies characterize leptin metabolism
in ESRD as maladaptive, then interventions to prevent or
reduce leptin accumulation would be desirable. Based on
emerging information, interventions that can potentially
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normalize leptin levels in ESRD patients include control of
body weight [6], use of high flux dialyzers [9], and renal
transplantation [10]. The present report by Fouque et al
identifies recombinant human IGF-I as another agent for
correction of uremic hyperleptinemia [7], should studies
establish a compelling rationale for so doing.
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